Phthalimide conjugation as a strategy for in vivo target protein degradation

Winter, Georg E., Buckley, Dennis L., Paulk, Joshiawa, Roberts, Justin M., Souza, Amanda, Dhe-Paganon, Sirano, Bradner, James E.·2015·Science

DOI 10.1126/science.aab1433

Cited by (1,004)

Items 601–700 of 1,004

Discovery of BWA-522 , a First-in-Class and Orally Bioavailable PROTAC Degrader of the Androgen Receptor Targeting N-Terminal Domain for the Treatment of Prostate Cancer
Bowen Zhang, Chang Liu, Zhenqian Yang, Sai Zhang, Xiaolin Hu, Baohu Li, Mei Mao, Xiao Wang, Zhuoyue Li, Shumin Ma et al. · 2023 · Journal of Medicinal Chemistry
Click chemistry in the development of PROTACs
Ce Yang, Ravi S. Tripathi, Binghe Wang · 2023 · RSC Chemical Biology
The cyclimids: Degron-inspired cereblon binders for targeted protein degradation
Saki Ichikawa, N. Connor Payne, Wenqing Xu, Chia‐Fu Chang, Nandini Vallavoju, Spencer Frome, Hope A. Flaxman, Ralph Mazitschek, Christina M. Woo · 2024 · Cell chemical biology
Optimization of a “bump-and-hole” approach to allele-selective BET bromodomain inhibition
Andrew C. Runcie, Michael Zengerle, Kwok-Ho Chan, A. Testa, L. van Beurden, Matthias G. J. Baud, Ola Epemolu, Lucy C.J. Ellis, Kevin D. Read, V. Coulthard et al. · 2018 · Chemical Science
Protein stability and degradation in health and disease
Lene Clausen, Amanda B. Abildgaard, Sarah K. Gersing, Amelie Stein, Kresten Lindorff‐Larsen, Rasmus Hartmann‐Petersen · 2018 · Advances in protein chemistry and structural biology
Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites
Michael D. Olp, Daniel J. Sprague, Christopher J. Goetz, Stefan G. Kathman, Sarah L. Wynia‐Smith, Shifali Shishodia, Steven B. Summers, Ziyang Xu, Alexander V. Statsyuk, Brian C. Smith · 2020 · ACS Chemical Biology
The therapeutic potential of PROTACs
Andrew B. Benowitz, Katherine L. Jones, John D. Harling · 2020 · Expert Opinion on Therapeutic Patents
CDK Family PROTAC Profiling Reveals Distinct Kinetic Responses and Cell Cycle–Dependent Degradation of CDK2
Kristin M. Riching, Marie K. Schwinn, James D. Vasta, Matthew B. Robers, Thomas Machleidt, Marjeta Urh, Danette L. Daniels · 2020 · SLAS DISCOVERY
AZD5438-PROTAC: A selective CDK2 degrader that protects against cisplatin- and noise-induced hearing loss
Santanu Hati, Marisa Zallocchi, Robert A. Hazlitt, Yuju Li, Sarath Vijayakumar, Jaeki Min, Zoran Ranković, Sándor Lovas, Jian Zuo · 2021 · European Journal of Medicinal Chemistry
Selectivity through Targeted Protein Degradation (TPD)
Ariamala Gopalsamy · 2022 · Journal of Medicinal Chemistry
Regulation of Nuclear Receptors PXR and CAR by Small Molecules and Signal Crosstalk: Roles in Drug Metabolism and Beyond
Shyaron Poudel, Andrew D. Huber, Taosheng Chen · 2022 · Drug Metabolism and Disposition
Multi-therapies Based on PARP Inhibition: Potential Therapeutic Approaches for Cancer Treatment
Jie Zhang, Yuqi Gao, Zipeng Zhang, Jinbo Zhao, Wenshuang Jia, Chengcai Xia, Fugang Wang, Tingting Liu · 2022 · Journal of Medicinal Chemistry
BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis
Thomas C. Roberts, Usue Etxaniz, Alessandra Dall’Agnese, Shwu-Yuan Wu, Cheng‐Ming Chiang, Paul E. Brennan, Matthew J. A. Wood, Prem Puri · 2017 · Scientific Reports
Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers
Markus Schick, Stefan Habringer, Jonas A. Nilsson, Ulrich Bernd Keller · 2017 · British Journal of Haematology
The c‐MYC–BMI1 axis is essential for SETDB1‐mediated breast tumourigenesis
Jin‐Fen Xiao, Qiao‐Yang Sun, Ling‐Wen Ding, Wenwen Chien, Xinyu Liu, Anand Mayakonda, Yan‐Yi Jiang, Xin-Yi Loh, Xue‐Bin Ran, Ngan Doan et al. · 2018 · The Journal of Pathology
Biology and Therapy of Dominant Fusion Oncoproteins Involving Transcription Factor and Chromatin Regulators in Sarcomas
Jennifer A. Perry, Bo Kyung A. Seong, Kimberly Stegmaier · 2018 · Annual Review of Cancer Biology
Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations
Su Lin Lim, Alisa Damnernsawad, Pavithra Shyamsunder, Wee Joo Chng, Bing Han, Liang Xu, Jian Pan, Pushkar Dakle, Serhan Alkan, Jeffrey W Tyner et al. · 2019 · Haematologica
Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma
Yan Y. Song, Paul M.C. Park, Lei Wu, Arghya Ray, S. Picaud, Deyao Li, Virangika K. Wimalasena, Ting Du, P. Filippakopoulos, Kenneth Carl Anderson et al. · 2019 · Leukemia
The HMOX1 Pathway as a Promising Target for the Treatment and Prevention of SARS-CoV-2 of 2019 (COVID-19)
Neelu Batra, Cristabelle De Souza, Jyoti Batra, Alan G. Raetz, Ai‐Ming Yu · 2020 · International Journal of Molecular Sciences
Bifunctional HDAC Therapeutics: One Drug to Rule Them All?
Joshua P. Smalley, Shaun M. Cowley, James T. Hodgkinson · 2020 · Molecules
Small-Molecule Approaches to Targeted Protein Degradation
Tyler B. Faust, Katherine A. Donovan, Hong Yue, Philip P. Chamberlain, Eric S. Fischer · 2020 · Annual Review of Cancer Biology
USP15 antagonizes CRL4 CRBN -mediated ubiquitylation of glutamine synthetase and neosubstrates
Thang Van Nguyen · 2021 · Proceedings of the National Academy of Sciences
An update of label-free protein target identification methods for natural active products
Zhao Cui, Caifeng Li, Peng Chen, Hongjun Yang · 2022 · Theranostics
Cullin-RING ligases employ geometrically optimized catalytic partners for substrate targeting
Jerry Li, Nicholas Purser, Joanna Liwocha, Daniel C. Scott, Holly A. Byers, Barbara A. Steigenberger, Spencer Hill, Ishita Tripathi‐Giesgen, Trent B. Hinkle, Fynn M. Hansen et al. · 2024 · Molecular Cell
Degradation of Akt using protein-catalyzed capture agents
Ryan K. Henning, Joseph O. Varghese, Samir Das, Arundhati Nag, Grace Y. Tang, Kevin Tang, Alexander M. Sutherland, James R. Heath · 2016 · Journal of Peptide Science
Targeted protein degradation mechanisms
Yi Zhang, Christine Loh, Jesse Chen, Nello Mainolfi · 2019 · Drug Discovery Today Technologies
Chemically Induced Cellular Proteolysis: An Emerging Therapeutic Strategy for Undruggable Targets.
Seonghyeon Moon, Byung‐Hoon Lee · 2018 · Europe PMC (PubMed Central)
Development of a PDEδ‐Targeting PROTACs that Impair Lipid Metabolism
Michael Winzker, Alexandra Friese, Uwe Koch, Petra Janning, Slava Ziegler, Herbert Waldmann · 2019 · Angewandte Chemie International Edition
Development of photocontrolled BRD4 PROTACs for tongue squamous cell carcinoma (TSCC)
Zhenzhen Li, Siyue Ma, Xingye Yang, Ling Zhang, Liang Dong, Gaopan Dong, Lüpei Du, Zhenghua Lv, Minyong Li · 2021 · European Journal of Medicinal Chemistry
A direct high-throughput protein quantification strategy facilitates discovery and characterization of a celastrol-derived BRD4 degrader
Payne, N. Connor, Maksoud, Semer, Tannous, Bakhos A., Mazitschek, Ralph · 2022 · Cell Chemical Biology
Targeted Protein Degradation to Overcome Resistance in Cancer Therapies: PROTAC and N-Degron Pathway
Hanbyeol Kim, Jeongbae Park, Jeong‐Mok Kim · 2022 · Biomedicines
Structural rationalization of GSPT1 and IKZF1 degradation by thalidomide molecular glue derivatives
Radosław P. Nowak, Jianwei Che, Silas Ferrao, Nikki R. Kong, Hu Liu, Breanna L. Zerfas, Lyn H. Jones · 2023 · RSC Medicinal Chemistry
Deregulated transcription factors in the emerging cancer hallmarks
Adria Hasan, Naushad Ahmad Khan, Shahab Uddin M.S., Abdul Q. Khan, Martin S. Steinhoff · 2023 · Seminars in Cancer Biology
Mechanism of millisecond Lys48-linked poly-ubiquitin chain formation by cullin-RING ligases
Joanna Liwocha, Jerry Li, Nicholas Purser, Chutima Rattanasopa, Samuel A. Maiwald, David T. Krist, Daniel C. Scott, Barbara A. Steigenberger, Jesuraj Rajan Prabu, Brenda Arlene Schulman et al. · 2024 · Nature Structural & Molecular Biology
Surface Probing by Fragment-Based Screening and Computational Methods Identifies Ligandable Pockets on the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase
Xavier Lucas, Inge Van Molle, Alessio Ciulli · 2018 · Journal of Medicinal Chemistry
Aberrant Activation of NF-κB Signalling in Aggressive Lymphoid Malignancies
Ruth Kennedy, Ulf Klein · 2018 · Cells
Pomalidomide hybrids act as proteolysis targeting chimeras: Synthesis, anticancer activity and B-Raf degradation
Hong Chen, Feihong Chen, Sinan Pei, Shaohua Gou · 2019 · Bioorganic Chemistry
Monitoring protein communities and their responses to therapeutics
Hanna G. Budayeva, Donald S. Kirkpatrick · 2020 · Nature Reviews Drug Discovery
The novel cereblon modulator CC-885 inhibits mitophagy via selective degradation of BNIP3L
Bingbing Hao, Xiaojing Li, Xinglong Jia, Yuxing Wang, Linhui Zhai, Duanzhuo Li, Jie Liu, Die Zhang, Yu-Lu Chen, Yonghu Xu et al. · 2020 · Acta Pharmacologica Sinica
Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery
Jiayue Xi, Ruyue Zhang, Ke Chen, Lin Yao, Muqiong Li, Ru Jiang, Xiaoye Li, Li Fan · 2022 · Bioorganic Chemistry
Targeted Degradation of the Oncogenic Phosphatase SHP2
Vemulapalli, Vidyasiri, Donovan, Katherine A., Seegar, Tom C. M., Rogers, Julia M., Bae, Munhyung, Lumpkin, Ryan J., Cao, Ruili, Henke, Matthew T., Ray, Soumya S., Fischer, Eric S. et al. · 2021 · Biochemistry
Development of NanoLuc-targeting protein degraders and a universal reporter system to benchmark tag-targeted degradation platforms
Grohmann, Christoph, Magtoto, Charlene M., Walker, Joel R., Chua, Ngee Kiat, Gabrielyan, Anna, Hall, Mary, Cobbold, Simon A., Mieruszynski, Stephen, Brzozowski, Martin, Simpson, Daniel S. et al. · 2022 · Nature Communications
Ligation to Scavenging Strategy Enables On-Demand Termination of Targeted Protein Degradation
Yuhui Jin, Jing Fan, Ruyan Wang, Xuanyu Wang, Ning Li, Qidong You, Zhengyu Jiang · 2023 · Journal of the American Chemical Society
The application of PROTAC in HDAC
Shaoting Chen, Yuxiang Zheng, Benji Liang, Yudong Yin, Jian Yao, Quande Wang, Yanghan Liu, Nouri Neamati · 2023 · European Journal of Medicinal Chemistry
Proteolysis Targeting Chimera Degraders of the METTL3–14 m 6 A-RNA Methyltransferase
Francesco Errani, Annalisa Invernizzi, Marcin Herok, Elena Bochenkova, Fiona Stamm, Ivan Corbeski, Valeria Romanucci, Giovanni Di Fabio, František Zálešák, Amedeo Caflisch · 2024 · JACS Au
Alkylamine-tethered molecules recruit FBXO22 for targeted protein degradation
Chrysanthi Kagiou, Jose Antonio Cisneros, Jakob Farnung, Joanna Liwocha, Fabian Offensperger, Kevin D. Dong, Ka Yang, Gary Tin, Christina S. Horstmann, Matthias Hinterndorfer et al. · 2024 · Nature Communications
Small molecules as tools to study the chemical epigenetics of lysine acetylation
Matthias Schiedel, Stuart J. Conway · 2018 · Current Opinion in Chemical Biology
N-Heterocyclic Carbene-Catalyzed Enantioselective Synthesis of Spiro-glutarimides via α,β-Unsaturated Acylazoliums
Santigopal Mondal, Arghya Ghosh, Subrata Mukherjee, Akkattu T. Biju · 2018 · Organic Letters
Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications
Diana Reyes-Garau, Marcelo Lima Ribeiro, Gaël Roué · 2019 · Cancers
Development of cell-permeable peptide-based PROTACs targeting estrogen receptor α
Yuxuan Dai, Yue Na, Junni Gong, Chunxia Liu, Qifei Li, Jiaqi Zhou, Wenlong Huang, Hai Qian · 2019 · European Journal of Medicinal Chemistry
Homogeneous and Functional Group Tolerant Ring-Closing Metathesis for DNA-Encoded Chemical Libraries
Olivier B. C. Monty, Pranavanand Nyshadham, Kurt M. Bohren, Murugesan Palaniappan, Martin Matthew Matzuk, Damian W. Young, Nicholas Simmons · 2020 · ACS Combinatorial Science
PROTACs: New method to degrade transcription regulating proteins
Bei-Chen Hu, Yirong Zhou, Dejuan Sun, Yueying Yang, Yang Liu, Xingzhou Li, Hua Li, Lixia Chen · 2020 · European Journal of Medicinal Chemistry
Berberine: A Promising Natural Isoquinoline Alkaloid for the Development of Hypolipidemic Drugs
Dong‐Dong Li, Pan Yu, Wei Xiao, Zhenzhong Wang, Lin-Guo Zhao · 2020 · Current Topics in Medicinal Chemistry
Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation
Liang Jiang, Yuting Wang, Qian Li, Zhengchao Tu, Sihua Zhu, Sanfang Tu, Zhang Zhang, Ke Ding, Xiaoyun Lu · 2020 · Acta Pharmaceutica Sinica B
Targeting Histone Modifications in Breast Cancer: A Precise Weapon on the Way
Wei Li, Hao Wu, Shiyao Sui, Qin Wang, Shouping Xu, Da Pang · 2021 · Frontiers in Cell and Developmental Biology
Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure–Activity Relationship Studies
Xufen Yu, Jia Xu, Yudao Shen, Kaitlyn M. Cahuzac, Kwang‐Su Park, Brandon Dale, Jing Liu, Ramon E. Parsons, Jian Jun Jin · 2022 · Journal of Medicinal Chemistry
Development of Photolenalidomide for Cellular Target Identification
Zhi Lin, Yuka Amako, Farah Kabir, Hope A. Flaxman, Bogdan Budnik, Christina M. Woo · 2022 · Journal of the American Chemical Society
Inducing Protein Degradation as a Therapeutic Strategy
Craig M. Crews · 2017 · Journal of Medicinal Chemistry
Development of inhibitors targeting glycogen synthase kinase-3β for human diseases: Strategies to improve selectivity
Wei, Junxia, Wang, Jiaxing, Zhang, Jifa, Yang, Jinliang, Wang, Guan, Wang, Yuxi · 2022 · European Journal of Medicinal Chemistry
PROTACS: A technology with a gold rush-like atmosphere
Yuwei Wang, Li Lan, Min Wang, Jinyang Zhang, Yuhui Gao, Lei Shi, Li‐Ping Sun · 2022 · European Journal of Medicinal Chemistry
Progress in the controllability technology of PROTAC
Xin Wen He, Zhibing Weng, Yi Zou · 2023 · European Journal of Medicinal Chemistry
Degraders in epigenetic therapy: PROTACs and beyond
Xing‐Jie Dai, Shi‐Kun Ji, Meng‐Jie Fu, Gao-Zhi Liu, Huimin Liu, Shaopeng Wang, Liang Shen, Ning Wang, Piet A. Herdewijn, Yi‐Chao Zheng et al. · 2024 · Theranostics
Orally Bioavailable Proteolysis-Targeting Chimeras: An Innovative Approach in the Golden Era of Discovering Small-Molecule Cancer Drugs
Rohan Kalyan Rej, Srinivasa Rao Allu, Joyeeta Roy, Ranjan Kumar Acharyya, I. N. Chaithanya Kiran, Yesu Addepalli, V. Dhamodharan · 2024 · Pharmaceuticals
Induced proximity-based therapeutic modalities
Elizabeth A. King, Margot Meyers, Daniel K. Nomura · 2025 · Nature Reviews Drug Discovery
Epigenetic drugs in cancer therapy: mechanisms, immune modulation, and therapeutic applications
Chen Ma, Junkai Cheng, Jian Hong Gu, Qin Wang · 2025 · Molecular Biomedicine
Targeting Histone Acetylation
Christopher Brent Benton, Warren C. Fiskus, Kapil N. Bhalla · 2017 · The Cancer Journal
New Drugs in Multiple Myeloma
Chutima Kunacheewa, Robert Zygmunt Orlowski · 2019 · Annual Review of Medicine
Development and biological applications of sulfur–triazole exchange (SuTEx) chemistry
Adam L. Borne, Jeffrey W. Brulet, Kun Yuan, Ku‐Lung Hsu · 2021 · RSC Chemical Biology
Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders
Nisha Setia, Haider Thaer Abdulhameed Almuqdadi, Mohammad Abid · 2023 · European Journal of Medicinal Chemistry
Practical synthesis of a phthalimide-based Cereblon ligand to enable PROTAC development
Jasmin Lohbeck, Aubry K. Miller · 2016 · Bioorganic & Medicinal Chemistry Letters
Structural insights into substrate recognition by the SOCS2 E3 ubiquitin ligase
Wei-Wei Kung, Sarath Ramachandran, Nikolai Makukhin, Elvira Bruno, Alessio Ciulli · 2019 · Nature Communications
Identification and selectivity profiling of small-molecule degraders via multi-omics approaches
Natalie S. Scholes, Cristina Mayor‐Ruiz, Georg E. Winter · 2021 · Cell chemical biology
Inhibitors, PROTACs and Molecular Glues as Diverse Therapeutic Modalities to Target Cyclin-Dependent Kinase
Sandeep Rana, Jayapal Reddy Mallareddy, Sarbjit Singh, Lidia Boghean, Amarnath Natarajan · 2021 · Cancers
Recent advances in targeted protein degraders as potential therapeutic agents
Na Yang, Bo Kong, Zhaohong Zhu, Fei Huang, Liliang Zhang, Tao Lu, Yadong Chen, Yanmin Zhang, Yulei Jiang · 2023 · Molecular Diversity
Niedermolekulare PROTACs: neue Wege zum Abbau von Proteinen
Toure, Momar, Crews, Craig M. · 2016 · Angewandte Chemie
Cereblon-Recruiting PROTACs: Will New Drugs Have to Face Old Challenges?
Marcin Cieślak, Marta Słowianek · 2023 · Pharmaceutics
Click Chemistry and Targeted Degradation: A Winning Combination for Medicinal Chemists?
Anna Pasieka, Eleonora Diamanti, Elisa Uliassi, María Laura Bolognesi · 2023 · ChemMedChem
Transcriptional Elongation of HSV Immediate Early Genes by the Super Elongation Complex Drives Lytic Infection and Reactivation from Latency
Roberto Alfonso, Anne‐Marie W. Turner, Pierre M. Jean Beltran, Jesse H. Arbuckle, Hanna G. Budayeva, Ileana M. Cristea, Thomas M. Kristie · 2017 · Cell Host & Microbe
Neue Modalitäten für schwierige Zielstrukturen in der Wirkstoffentwicklung
Eric Valeur, Stéphanie M. Guéret, Hélène Adihou, Ranganath Gopalakrishnan, Malin Lemurell, Herbert Waldmann, Tom N. Grossmann, Alleyn T. Plowright · 2017 · Angewandte Chemie
Phosphine‐Activated Lysine Analogues for Fast Chemical Control of Protein Subcellular Localization and Protein SUMOylation
Joshua S. Wesalo, Ji Luo, Kunihiko Morihiro, Jihe Liu, Alexander Deiters · 2019 · ChemBioChem
Native Mass Spectrometry for the Study of PROTAC GNE‐987‐Containing Ternary Complexes
Louise M. Sternicki, Jim Nonomiya, Miaomiao Liu, Melinda M. Mulvihill, Ronald J. Quinn · 2021 · ChemMedChem
Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile
Chaowei Ren, Ning Sun, Haixia Liu, Ying Kong, Renhong Sun, Xing Qiu, Jinju Chen, Yan Li, Jianshui Zhang, Yuedong Zhou et al. · 2021 · Journal of Medicinal Chemistry
Controlling PROTACs with Light
Shreya Verma, Debasish Manna · 2020 · ChemMedChem
Discovery of novel BTK PROTACs with improved metabolic stability via linker rigidification strategy
Song Chen, Zhendong Chen, Lixue Lu, Yunpeng Zhao, Ronghui Zhou, Qiong Xie, Yongzhi Shu, Jun Lin, Xufen Yu, Yonghui Wang · 2023 · European Journal of Medicinal Chemistry
Therapeutic Oligonucleotides: An Outlook on Chemical Strategies to Improve Endosomal Trafficking
Priyanka Mangla, Quentin Vicentini, Annabelle Biscans · 2023 · Cells
Targeted Protein Degradation through Recruitment of the CUL4 Complex Adaptor Protein DDB1
Margot Meyers, Sabine Cismoski, Anoohya Panidapu, Barbara Chie-Leon, Daniel K. Nomura · 2024 · ACS Chemical Biology
Targeting the Undruggable: Recent Progress in PROTAC-Induced Transcription Factor Degradation
Hyein Jung, Yeongju Lee · 2025 · Cancers
Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
Gang Fan, Shilin Chen, Qingping Zhang, Na Yu, Ziyang Shen, Zhaoji Liu, Weiming Guo, Zhi‐Han Tang, Jing Yang, Miao Liu · 2025 · MedComm
Disruption of mammalian SWI/SNF and polycomb complexes in human sarcomas: mechanisms and therapeutic opportunities
Matthew J. McBride, Cigall Kadoch · 2018 · The Journal of Pathology
Chemical Protein Degradation Approach and its Application to Epigenetic Targets
Yukihiro Itoh · 2018 · The Chemical Record
Discovery of potential asthma targets based on the clinical efficacy of Traditional Chinese Medicine formulas
Yu Wang, Yan‐Jiao Chen, Cheng Xiang, Guang-Wei Jiang, Yu‐Dong Xu, Lei-Miao Yin, Dongdong Zhou, Yanyan Liu, Yong‐Qing Yang · 2020 · Journal of Ethnopharmacology
Traceless Staudinger ligation enabled parallel synthesis of proteolysis targeting chimera linker variants
Troy A. Bemis, James J. La Clair, Michael D. Burkart · 2020 · Chemical Communications
ZMYND11-MBTD1 induces leukemogenesis through hijacking NuA4/TIP60 acetyltransferase complex and a PWWP-mediated chromatin association mechanism
Jie Li, Phillip M. Galbo, Weida Gong, Aaron J. Storey, Yi‐Hsuan Tsai, Xufen Yu, Jeong Hyun Ahn, Yiran Guo, Samuel G. Mackintosh, Ricky D. Edmondson et al. · 2021 · Nature Communications
PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs
Marı́a Maneiro, Elena De Vita, Daniel Conole, Cyrille S. Kounde, Qisi Zhang, Edward W. Tate · 2021 · Progress in medicinal chemistry
Is PROTAC technology really a game changer for central nervous system drug discovery?
Kayla Farrell, Timothy J. Jarome · 2021 · Expert Opinion on Drug Discovery
Identification and validation of selective deubiquitinase inhibitors
Anthony C. Varca, Dominick E. Casalena, Wai Cheung Chan, Bin Hu, Robert S. Magin, Rebekka M. Roberts, Xiaoxi Liu, He Zhu, Hyuk‐Soo Seo, Sirano Dhe‐Paganon et al. · 2021 · Cell chemical biology
Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles
Alberto Juan, María del Mar Noblejas‐López, María Arenas-Moreira, Carlos Alonso‐Moreno, Alberto Ocaña · 2022 · Frontiers in Cell and Developmental Biology
Targeted Protein Degradation Technology and Nanomedicine: Powerful Allies against Cancer
Jia‐Yi Lin, Haijun Liu, Ye Wu, Jin‐Mei Jin, Yudong Zhou, Hong Zhang, Dale G. Nagle, Hongzhuan Chen, Weidong Zhang, Xin Luan · 2023 · Small
PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities
Xuelian Liu, Anjin Wang, Yuying Shi, Mengyuan Dai, Miao Liu, Hongbing Cai · 2023 · Molecules
Targeting bromodomain-containing proteins: research advances of drug discovery
Zhaoping Pan, Yuxi Zhao, Xiaoyun Wang, Xin Xie, Mingxia Liu, Kaiyao Zhang, Lian Wang, Ding Bai, Leonard J. Foster, Rui Shu et al. · 2023 · Molecular Biomedicine